A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Paclitaxel
Related studies linked through entity extraction aliases.
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
- Status
- RECRUITING
- Phase
- PHASE1
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Status
- RECRUITING
- Phase
- PHASE3
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE1/PHASE2
Myeloprotection With Trilaciclib in Pan-cancer Population
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
- Status
- RECRUITING
- Phase
- PHASE2
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
- Status
- RECRUITING
- Phase
- PHASE2
Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2